SCHEMBL19434778

SCHEMBL19434778

COCCNS(=O)(=O)c1ccc(-c2ccc3nc(N4CCC(c5nc(C(C)C)no5)CC4)sc3n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 14/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ GPR183 P32249 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ KCNH2 Q12809 1/20 0.36
▸ HRH3 Q9Y5N1 1/20 0.36
▸ HTT P42858 1/20 0.35
▸ BRD4 O60885 1/20 0.34
▸ BRD2 P25440 1/20 0.34
▸ BRD3 Q15059 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19434924 0.90 GPR119 (0.43) GPR119CYP3A4CYP2C19GPR183LMNA
SCHEMBL19434768 0.88 GPR119 (0.46) GPR119CYP3A4CYP2C19GPR183LMNA
SCHEMBL29504487 0.86 MKNK1 (0.41) GPR119CYP3A4CYP2C19ALDH1A1HPGD
SCHEMBL19434950 0.86 MKNK1 (0.41) GPR119CYP3A4CYP2C19ALDH1A1HPGD
SCHEMBL19434948 0.85 GPR119 (0.55) GPR119CYP3A4CYP2C19GPR183CNR2
SCHEMBL19434782 0.81 GPR119 (0.44) GPR119CYP3A4CYP2C19GPR183ALDH1A1
SCHEMBL29850886 0.81 GPR119 (0.52) GPR119CYP3A4CYP2C19GPR183LMNA
SCHEMBL19434844 0.81 GPR119 (0.52) GPR119CYP3A4CYP2C19GPR183LMNA
SCHEMBL19454580 0.80 CNR2 (0.51) GPR119CYP3A4CYP2C19ALDH1A1CNR2
SCHEMBL19449830 0.80 SCN9A (0.41) GPR119CYP3A4CYP2C19ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3440087-B1 THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS MANKIND PHARMA LTD (IN) 2022-08-10 — — EP claimed
CN-109415381-B Thiazolopyridine derivatives as GPR119 agonists 人类制药有限公司 2022-03-25 — — CN claimed
EP-3440087-A1 THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS MANKIND PHARMA LTD (IN) 2019-02-13 — — EP claimed
US-20170291910-A1 NOVEL COMPOUNDS AS GPR119 AGONISTS MANKIND PHARMA LTD. (IN) 2017-10-12 — — US claimed
WO-2017175068-A1 THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS MANKIND PHARMA LTD. (IN) 2017-10-12 — — WO claimed
EP-3440087-B1 THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS MANKIND PHARMA LTD (IN) 2022-08-10 — — EP disclosed
CN-109415381-B Thiazolopyridine derivatives as GPR119 agonists 人类制药有限公司 2022-03-25 — — CN disclosed
US-10919915-B2 Compounds as GPR119 agonists MANKIND PHARMA LTD. (IN) 2021-02-16 — — US disclosed
US-10919915-B2 Compounds as GPR119 agonists MANKIND PHARMA LTD. (IN) 2021-02-16 — — US disclosed
US-20200040006-A1 NOVEL COMPOUNDS AS GPR119 AGONISTS MANKIND PHARMA LTD. (IN) 2020-02-06 — — US disclosed
US-20200040006-A1 NOVEL COMPOUNDS AS GPR119 AGONISTS MANKIND PHARMA LTD. (IN) 2020-02-06 — — US disclosed
EP-3440087-A1 THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS MANKIND PHARMA LTD (IN) 2019-02-13 — — EP disclosed
US-20170291910-A1 NOVEL COMPOUNDS AS GPR119 AGONISTS MANKIND PHARMA LTD. (IN) 2017-10-12 — — US disclosed
US-20170291910-A1 NOVEL COMPOUNDS AS GPR119 AGONISTS MANKIND PHARMA LTD. (IN) 2017-10-12 — — US disclosed
WO-2017175068-A1 THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS MANKIND PHARMA LTD. (IN) 2017-10-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040006-A1 NOVEL COMPOUNDS AS GPR119 AGONISTS GPR119, GPR84, GPR65 GPR119 1/4885CYP3A4 2006/4885CYP2C19 1094/4885
US-20170291910-A1 NOVEL COMPOUNDS AS GPR119 AGONISTS GPR119, GPR84, GPR65 GPR119 1/4885CYP3A4 2006/4885CYP2C19 1094/4885
US-10919915-B2 Compounds as GPR119 agonists GPR119, GPR84, GPR65 GPR119 1/4885CYP3A4 1458/4885CYP2C19 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback